Genscript Biotech Corporation (FRA:G51)
Germany flag Germany · Delayed Price · Currency is EUR
1.625
-0.009 (-0.55%)
At close: Dec 5, 2025

Genscript Biotech Company Description

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally.

It operates through three segments: Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products.

The Life Science Services and Products segment provides products and services in various categories, including gene synthesis, oligonucleotide synthesis, peptide synthesis, protein engineering, antibody development, and life-science equipment and consumables, such as molecular diagnostics tools and genome editing materials for biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and the food industry.

The Biologics Development Services segment which helps biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene/cell therapy products with an integrated platform.

The Industrial Synthetic Biology Products segment develops and produces industrial enzymes through non-pathogenic microbial strains constructed using genetic engineering.

Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People’s Republic of China.

Genscript Biotech Corporation
Country Cayman Islands
Founded 2002
Industry Commercial Physical and Biological Research
Employees 5,568
CEO Weihui Shao

Contact Details

Address:
Jiangning Science Park
Nanjing, 211100
China
Phone 86 25 5889 7288
Website genscript.com

Stock Details

Ticker Symbol G51
Exchange Frankfurt Stock Exchange
Fiscal Year January - December
Reporting Currency USD
SIC Code 8731

Key Executives

Name Position
Weihui Shao Chief Executive Officer
Josie Zhou Chief Financial Officer
Weihui Shao Chief Operating Officer